-
Mashup Score: 0Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win - 2 year(s) ago
Sanofi and Regeneron’s Dupixent, also known as dupilumab, notched a win in a phase 3 study of patients with eosinophilic esophagitis (EoE), Sanofi said in a late-breaking abstract debuted Saturday at the 2022 annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI).
Source: FiercePharmaCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3UPDATED: Pfizer to join J&J, Moderna in shareholder vote showdown on vaccine pricing strategy, manufacturing tech sharing - 2 year(s) ago
Throughout the global push to produce COVID-19 vaccines, pharma companies have frequently come under fire for unequal access to their shots. Oxfam, in a bid to force better access, has scored a series of wins in its effort to exact pricing and intellectual property information from Johnson & Johnson, Pfizer and Moderna.
Source: FiercePharmaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Bravo @Oxfam Pfizer to join J&J, Moderna in shareholder vote showdown on vaccine pricing strategy, manufacturing tech sharing https://t.co/G7ZUhqWmvu
-
-
Mashup Score: 0Women's telehealth startup Alloy turns up the heat on men to bring attention to menopause symptoms - 2 year(s) ago
A newly launched women’s telehealth and prescription delivery service founded by a longtime women’s magazine editor literally puts men in the hot seat while pondering the question: “What if hot flashes happened to men?”
Source: FiercePharmaCategories: Future of Medicine, Latest HeadlinesTweet-
#Womenshealth #telehealth startup Alloy turns up the heat on men to bring attention to #menopause symptoms | #femtech https://t.co/GkpSnpO1xh
-
-
Mashup Score: 0Women's telehealth startup Alloy turns up the heat on men to bring attention to menopause symptoms - 2 year(s) ago
A newly launched women’s telehealth and prescription delivery service founded by a longtime women’s magazine editor literally puts men in the hot seat while pondering the question: “What if hot flashes happened to men?”
Source: FiercePharmaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Women's telehealth startup Alloy turns up the heat on men to bring attention to menopause symptoms https://t.co/20py1CJl6o #telemedicine #telehealth #technology #healthcare #artificialintelligence #digitalhealth #behavioralhealth #mentalhealth #connectedhealth
-
-
Mashup Score: 1Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder - 2 year(s) ago
More than a decade after its founding, Agios Pharmaceuticals has its first FDA green light. With the approval for Pyrukynd to treat hemolytic anemia in adults with pyruvate kinase deficiency, the company is off and running in the commercial arena.
Source: FiercePharmaCategories: Hematologists1, Latest HeadlinesTweet-
RT @analystlandnews: Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder https://t.co/zIglJnz5i2 h…
-
-
Mashup Score: 02022 forecast: How marketers must learn from Biogen's marketing struggles with Aduhelm - 2 year(s) ago
The U.S. approval of the first new Alzheimer’s disease drug in nearly two decades caused a major boon in research, but, for marketers, the fallout from Biogen’s FDA green light for Aduhelm has put a major dampener on the party.
Source: FiercePharmaCategories: Hem/Oncs, Latest HeadlinesTweet-
@barttels2 @ProfRobHoward @macesari @biogen @BosBizRowan @LonSchneiderMD @jasonkarlawish @geoperry @MadhavThambiset @AlbertoEspay @gregggonsalves @MariaGlymour @reshmagar @samgandy @PhilAlz @drgdanielgeorge @CMSGov @ZacharyBrennan @EWidera @SECGov @FTC @mlythoe @GreenwallFdn @akesselheim @alzassociation How marketers must learn from @biogen 's marketing struggles with Aduhelm https://t.co/rMoptzaqCn via @PharmaceuticBen
-
-
Mashup Score: 0Roche, Novartis CEOs pull down $12M-plus each in 2021 pay - 2 year(s) ago
While crosstown rivals Roche and Novartis routinely rank among the world’s top five drugmakers by revenue, their CEOs typically fall outside the ranks of the top-paid CEOs in the industry. As for 2021, the CEOs of the Swiss drugmakers each collected more than $12 million in total pay.
Source: FiercePharmaCategories: Hem/Oncs, Latest HeadlinesTweet-
Roche, Novartis CEOs pull down $12M-plus each in 2021 pay https://t.co/7T4vRvlo0n
-
-
Mashup Score: 0
While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and pharma reps. Once COVID-19 stopped in-person meetings, HCPs soon realized that fewer rep interruptions in their day were actually a good thing and started limiting those contacts.
Source: FiercePharmaCategories: Healthcare Professionals, Latest HeadlinesTweet-
For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd | https://t.co/UHMbLYiZRB
-
-
Mashup Score: 0Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests - 2 year(s) ago
The future of cancer drug marketing will be about helping oncologists understand the complexities of precision medicine and how new advances in targeted therapies can help their specific patients. That means drug companies will need to focus less on the selling and more on the science.
Source: FiercePharmaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests https://t.co/At3boBXVvo
-
-
Mashup Score: 1Biogen used charity giving to illegally boost multiple sclerosis drug sales, Humana lawsuit says - 2 year(s) ago
For years, federal prosecutors have gone after drug companies for allegedly using charity contributions as a way to boost sales. Biogen was among the pharma players to ink a federal settlement, but, now, insurance giant Humana is targeting the company’s charity giving with a new lawsuit.
Source: FiercePharmaCategories: HIV/AIDS, Latest HeadlinesTweet-
RT @lowninstitute: Sources: https://t.co/5JTMgA1O1o @EricSFierce at @FiercePharma and https://t.co/rzpTVXbgxN @Morgan_Haefner at @BeckersHR
-
Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win https://t.co/yZwxTzklud